Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Probutate

FDA-approved product (cream, topical), marketed as Pandel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Probutate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Asthma
  • Atopic eczema
  • Bursitis
  • Cancer
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Exanthem
  • Eye inflammation
  • Hemorrhoid
  • Herpes Labialis
  • and 19 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, moderately potent (group ii)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Probutate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Probutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Vitamin C, Vitamin B1 and Steroid in Sepsis

    NCT04039815 · start 2019-12-03

    Registered record
    Registry ID
    NCT04039815
    Conditions
    Sepsis, Severe
    Interventions
    Ascorbic acid-Vitamin B1-Hydrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-12-03
    Completion
    2020-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis, Severe
    InterventionAscorbic acid-Vitamin B1-Hydrocortisone; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Analgesic Effect of Pulmonary Recruitment and Intraperitoneal Hydrocortisone in Laparoscopic Gynecological Surgery

    NCT03845608 · start 2019-03

    Registered record
    Registry ID
    NCT03845608
    Conditions
    Laparoscopic Gynecological Surgery
    Interventions
    Pulmonary Recruitment Maneuver
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-03
    Completion
    2019-11
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaparoscopic Gynecological Surgery
    InterventionPulmonary Recruitment Maneuver
    PhasePhase 4
    Registry statusUnknown

  • Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock

    NCT03821714 · start 2019-02-01

    Registered record
    Registry ID
    NCT03821714
    Conditions
    Septic Shock
    Interventions
    Glucocorticoid combination therapy; Glucocorticoid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2020-01-30
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionGlucocorticoid combination therapy; Glucocorticoid
    PhaseNot applicable
    Registry statusCompleted

  • Blessing or Curse? Combined Vitamin Therapy in Non Viral Septic Shock.

    NCT06152458 · start 2019-01-01

    Registered record
    Registry ID
    NCT06152458
    Conditions
    Septic Shock
    Interventions
    Vitamin C
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2020-03-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionVitamin C
    PhasePhase 4
    Registry statusCompleted

  • A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

    NCT03311932 · start 2018-04-16

    Registered record
    Registry ID
    NCT03311932
    Conditions
    Adrenal Insufficiency
    Interventions
    Infacort®; Cortef®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-16
    Completion
    2018-07-13
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Insufficiency
    InterventionInfacort®; Cortef®
    PhasePhase 1
    Registry statusCompleted

  • Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation

    NCT03907865 · start 2018-03-27

    Registered record
    Registry ID
    NCT03907865
    Conditions
    Dry Eye
    Interventions
    Softacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-27
    Completion
    2019-01-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionSoftacort
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock

    NCT03380507 · start 2018-03-17

    Registered record
    Registry ID
    NCT03380507
    Conditions
    Septic Shock; Critical Illness
    Interventions
    Triple therapy group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2018-03-17
    Completion
    2021-11-01
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Critical Illness
    InterventionTriple therapy group
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

    NCT02574910 · start 2017-08-01

    Registered record
    Registry ID
    NCT02574910
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-08-01
    Completion
    2023-06-03
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionAbiraterone acetate
    PhasePhase 1
    Registry statusTerminated

  • Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration

    NCT03178214 · start 2017-05-22

    Registered record
    Registry ID
    NCT03178214
    Conditions
    Adrenal Insufficiency
    Interventions
    Infacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-22
    Completion
    2017-07-26
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Insufficiency
    InterventionInfacort
    PhasePhase 1
    Registry statusCompleted

  • Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer

    NCT03047174 · start 2017-05-09

    Registered record
    Registry ID
    NCT03047174
    Conditions
    Head and Neck Neoplasms
    Interventions
    Mepitel® Film; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-05-09
    Completion
    2019-07-16
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms
    InterventionMepitel® Film; Standard Care
    PhaseNot applicable
    Registry statusCompleted

  • Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma

    NCT03165344 · start 2017-02-10

    Registered record
    Registry ID
    NCT03165344
    Conditions
    Esophageal Stenosis Acquired
    Interventions
    Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration); Triamcinolone Acetonide (route of administration); Prednisone (route of administration)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-02-10
    Completion
    2019-12-31
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Stenosis Acquired
    InterventionHydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration); Triamcinolone Acetonide (route of administration); Prednisone (route of administration)
    PhaseNot applicable
    Registry statusCompleted

  • Oral Calcitriol With Ketoconazole in CRPC

    NCT03261336 · start 2017-01-06

    Registered record
    Registry ID
    NCT03261336
    Conditions
    Castration-resistant Prostate Cancer
    Interventions
    Calcitriol, Ketoconazole, Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-01-06
    Completion
    2018-02-28
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-resistant Prostate Cancer
    InterventionCalcitriol, Ketoconazole, Hydrocortisone
    PhasePhase 2
    Registry statusTerminated

  • Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories

    NCT02671058 · start 2016-03

    Registered record
    Registry ID
    NCT02671058
    Conditions
    Healthy
    Interventions
    Cortenema; Hydrocortisone Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-05-24
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCortenema; Hydrocortisone Acetate
    PhasePhase 1
    Registry statusCompleted

  • Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    NCT02270788 · start 2015-04-02

    Registered record
    Registry ID
    NCT02270788
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Crenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04-02
    Completion
    2016-10-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCrenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    PhasePhase 1
    Registry statusCompleted

  • Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study

    NCT02044159 · start 2014-07

    Registered record
    Registry ID
    NCT02044159
    Conditions
    Shock
    Interventions
    Hydrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShock
    InterventionHydrocortisone; Placebo
    PhasePhase 4
    Registry statusCompleted